Andrew Cleeland is the CEO of Fogarty Innovation, a non-profit medtech incubator based in Silicon Valley. He is a seasoned executive with 30+ years in the medical device industry in both the private and public sectors.  Prior to joining Fogarty, he led Medtronic’s Transcatheter Mitral Valve business following its 2015 acquisition of Twelve Inc., where he was CEO.  Prior to Twelve, he was CEO of Ardian Inc. which was acquired by Medtronic in 2011. He currently serves on the boards of five companies: Fogarty Innovation, Zenflow Inc. (chairman), MMI Inc. (chairman), Francis Medical (chairman) and atHeart Medical. He also holds advisory positions at Longitude Capital, Arboretum Ventures, EQT Private Equity, and ClavystBio. He has also been invited to serve on the UCSF-Stanford Pediatric Device Consortium; and Singapore’s Agency for Science, Technology and Research - Medtech Catapult Program.